復星醫藥(02196.HK)附屬收購互聯網健康服務公司餘下股權
復星醫藥(02196.HK)公佈,昨日(26日)附屬公司復星健康,與公司控股股東復星高科技、復星高科技聯繫人有叻信息,及附屬公司佛山禪醫分別訂立協議,據此復星高科技同意向復星健康以3,400萬元人民幣(下同)的現金對價,出售復星高科技出售權益,另外有叻信息同意以1,000萬元向復星健康出售有叻信息出售權益,佛山禪醫同意以1,040.8萬元的對價,向復星健康出售佛山禪醫出售權益。復星健康向復星高科技、有叻信息及佛山禪醫,各自支付出售權益對價3,400萬元、1,000萬元及1,040.8萬元。
涉及出售權益佔從事提供互聯網健康諮詢及家庭健康管理服務的目標公司約45.2%的股權。在交易前,公司通過復星健康及佛山禪醫已經合計持有該公司約63.5%的股權,股權轉讓協議項下交易完成後,目標公司將成爲復星健康全資附屬公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.